MB 11316

Drug Profile

MB 11316

Alternative Names: MB11316

Latest Information Update: 27 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mazence
  • Developer KT&G Life Sciences
  • Class
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dry eyes

Most Recent Events

  • 31 Oct 2013 No development reported - Phase-II for Dry eyes in South Korea (unspecified route)
  • 30 Mar 2012 Mazence is now called KT&G Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top